PD-L1 IHC (Nivolumab) Urothelial Carcinoma
Also known as: OPDIVO®, Programmed Death Ligand 1
Use
The PD-L1 IHC test for nivolumab uses immunohistochemistry to evaluate the expression of PD-L1 protein in urothelial carcinoma. This expression can provide insights into the potential effectiveness of nivolumab, an immune checkpoint inhibitor that targets the PD-1 pathway. Studies have shown that nivolumab offers survival benefits and meaningful clinical benefits in patients with urothelial carcinoma that has progressed despite treatment with platinum-based therapies.
Special Instructions
Not provided.
Limitations
The PD-L1 IHC test is limited by its reliance on tissue specimens that have been formalin-fixed and paraffin-embedded. It is vital that the tissue samples be of adequate cellularity and that they originate from urothelial carcinoma tumors, as other tumor types may lead to sample rejection. Correct fixation in formalin is crucial to preserve tissue characteristics for accurate testing results.
Methodology
Immunoassay (IHC)
Biomarkers
PD-L1
Protein
LOINC Codes
- 83055-4 - PD-L1 by 28-8 Tiss Ql ImStn
- 83053-9 - Cells.PD-L1/Viab tum NFr Tiss ImStn
- 77202-0 - Laboratory comment Report
- 72486-4 - Lab director name Provider
Result Turnaround Time
2-5 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
One FFPE tissue block or five unstained slides.
Minimum Volume
Three unstained tissue slides
Container
Tissue block or slide
Collection Instructions
Tissue should be fixed in 10% neutral buffered formalin for no more than 72 hours. Embed in paraffin.
Storage Instructions
Room temperature
Causes for Rejection
Insufficient tissue; tumor other than urothelial carcinoma
Other tests from different labs that may be relevant